23. You have be ogy company for which process to manufact u have been asked to evaluate several investment opportunities for the biotechnol- y company for which you work. These potential investments concern a new rocess to manufacture a new, genetically engineered pharmaceutical. The financial information on the process alternatives are as follows: Capital Investment ($million) Case Yearly, After-Tax Cash Flow ($million/y) 15 Base Alternative 1 Alternative 2 Alternative 3 O O LO 25 30 For the alternatives, the capital investment and the yearly after-tax cash flows are incremental to the base case. The assumed plant life is 12 years, and all of the capital investment occurs at time = 0. a. If an acceptable, nondiscounted rate of return on investment (ROROI) is 25% p.a., which is the best option? b. If an acceptable, after-tax, discounted rate of return is 15% p.a., which option is the best